Journey™ UNI Post Market Clinical Follow-Up

The purpose of the current investigation is to assess the safety and effectiveness of the
JOURNEY UNI Unicompartmental Knee System (UKS) in patients with non-inflammatory degenerative
joint disease (NIDJD) of the knee who previously had the Journey UNI UKS implanted. This
clinical study will prospectively evaluate the 36 and 60-month safety and performance of the
JOURNEY UNI UKS in patients with NIDJD of the knee who required lateral or medial knee
compartment replacement.

Inclusion Criteria:

1. Between 12 and 48 months previously, subject had unicompartmental knee replacement
implanted for unicompartmental, NIDJD including OA, traumatic arthritis, avascular
necrosis, for correction of functional deformity, or to repair a fracture that was
unmanageable using other techniques.

2. Subject received a Journey UKS implant (consisting of a femoral component, tibial
baseplate, and a tibial insert).

3. Subject was considered skeletally mature at the time of surgery and was at least 18
years of age.

4. Subject is willing to have retrospective data collected and to participate in required
prospective follow-up visit(s) at the investigational site and to complete study
procedures and questionnaires.

5. Subject has consented to participate in the study by signing the Institutional Review
Board (IRB)/Ethics Committee (EC)-approved informed consent form (ICF).

Exclusion Criteria:

- Subject has Body Mass Index (BMI) > 40 within 1 month of surgery. 2. Subjects who have
received the Journey UNI UKS as part of a revision surgery.

3. Subject has a condition that may interfere with the unicompartmental knee
arthroplasty (UKA) survival or outcome (e.g. Paget's or Charcot's disease, vascular
insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal
insufficiency or neuromuscular disease).

4. Subject has a known allergy to study device or one or more of its components.

5. Subject, in the opinion of the Principal Investigator (PI), has an emotional or
neurological condition that would preempt his/her ability or willingness to
participate in the study including mental illness, mental retardation, drug or alcohol
abuse.

6. Subject is entered in another investigational drug, biologic, or device study or
has been treated with an investigational product in the past 30 days.

7. Subject is known to be at risk for loss to follow-up, or failure to return for
scheduled visits.